Durect Posts Narrower Loss in Fiscal Q2
Durect (NASDAQ:DRRX), a biopharmaceutical company focused on liver disease therapeutics, released results for the second quarter of fiscal 2025 on August 12, 2025. Durect posted better-than-expected earnings per share (GAAP) of $(0.07), surpassing analyst forecasts of $(0.13) (GAAP), and revenue (GAAP) of $0.45 million, above the $0.32 million consensus (GAAP). Both figures (GAAP EPS of -0.07 and GAAP revenue of $447,000) beat expectations, but revenue (GAAP) declined compared to the same period in 2024. The company’s cash position fell sharply, and its outlook now centers around a planned acquisition by Bausch Health. Overall, the period highlighted ongoing financial risk, operational cuts, and strategic uncertainty as Durect prepares to complete its merger.
Source: Analyst estimates for the quarter provided by FactSet.
Durect is a clinical-stage biopharmaceutical company that concentrates on therapies for liver diseases. Its main asset is larsucosterol, a drug candidate targeting alcohol-associated hepatitis (AH), a life-threatening liver condition for which there are currently no approved treatments. Durect also has legacy commercial products, but these make up a very small part of its business.
Source Fool.com
